[A23-32] Olaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 03.07.2023
Commission awarded on 03.04.2023 by the Federal Joint Committee (G-BA).
Maintenance treatment of adult patients with advanced BRCA1/2-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.